Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
C4 Therapeutics Inc (NASDAQ: CCCC) closed the day trading at $3.32 down -1.78% from the previous closing price of $3.38. In other words, the price has decreased by -$1.78 from its previous closing price. On the day, 1.24 million shares were traded. CCCC stock price reached its highest trading level at $3.58 during the session, while it also had its lowest trading level at $3.265.
Ratios:
For a better understanding of CCCC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The Stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned. The Stock a target price of $8.
On September 15, 2025, Stephens Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $6. On September 04, 2025, Guggenheim started tracking. The Stock assigning a Buy rating and target price of $8.Guggenheim initiated its Buy rating on September 04, 2025, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share. On Nov 18 ’24, another insider, Salter Malcolm, who serves as the Director of the company, bought 13,000 shares for $4.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 236287104 and an Enterprise Value of 84656104. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 6.90 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 2.472 whereas that against EBITDA is -0.696.
Stock Price History:
The Beta on a monthly basis for CCCC is 3.02, which has changed by -0.47716534 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $7.14, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of. The Stock is 33.62%, while the 200-Day Moving Average is calculated to be 34.71%.
Shares Statistics:
Over the past 3-months, CCCC traded about 1.61M shares per day on average, while over the past 10 days, CCCC traded about 1780990 shares per day. A total of 71.01M shares are outstanding, with a floating share count of 59.99M. Insiders hold about 15.72% of the company’s shares, while institutions hold 65.80% stake in the company. Shares short for CCCC as of 1756425600 were 3781945 with a Short Ratio of 2.35, compared to 1753920000 on 4656847. Therefore, it implies a Short% of Shares Outstanding of 3781945 and a Short% of Float of 5.74.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on. The Stock of the company. The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.2 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.37 and -$1.72 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$1.58, with 6.0 analysts recommending between -$1.13 and -$2.01.
Revenue Estimates
5 analysts predict $6.28M in revenue for the current quarter. It ranges from a high estimate of $8M to a low estimate of $5M. As of the current estimate, C4 Therapeutics Inc’s year-ago sales were $15.36MFor the next quarter, 5 analysts are estimating revenue of $6.48M. There is a high estimate of $9.5M for the next quarter, whereas the lowest estimate is $3M.
A total of 6 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $29.7M, while the lowest revenue estimate was $20.35M, resulting in an average revenue estimate of $25.48M. In the same quarter a year ago, actual revenue was $35.58M
